Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New...
A variety of national and local news outlets have highlighted AACR initiatives and experts in recent weeks. Learn about...
Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how...
We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference,...
The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next...
With seven CAR T-cell therapies approved by the U.S. Food and Drug Administration, this innovative immunotherapy has revolutionized the...
In July, the editors from AACR's 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution,...
The summer issue of Cancer Today includes articles about integrating patient-reported outcomes into clinical research and care, advances in...
During the opening session of the AACR Conference on Drug Discovery and Development, the conference cochairs—Patricia M. LoRusso, DO,...
At the recent AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers, AACR Immediate Past President...
Cancer immunology expert and former AACR president Elizabeth Jaffee, MD, FAACR, discusses the latest progress in the research on...